ReviewFrontiers in immunology2026
Deciphering immune-inflammatory dysregulation in the endometriotic microenvironment: insights from single-cell omics and artificial intelligence.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a prevalent chronic inflammatory gynecological disorder affecting approximately 10% of reproductive-age women worldwide, characterized by endometrial-like tissue outside the uterine cavity. Ectopic lesion growth tracks closely with immune-inflammatory dysregulation-altered macrophage polarization, impaired natural killer (NK) cytotoxicity, skewed T cell subsets, B cell-related autoimmunity, tolerogenic dendritic cells, mast cell-associated neuroinflammation, and abnormal cytokine networks. Even after many years of study, several regulatory mechanisms in the endometriotic microenvironment remain only partly defined. Single-cell omics-especially single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, mass cytometry (CyTOF), and multi-omics integration-maps immune composition and cell-cell communication at a level bulk assay typically miss, including rare states and niche structure. Artificial intelligence (AI) and machine learning (ML), including single-cell foundation models, deep learning for drug repurposing, immune deconvolution, and large language models, are now common choices for integrating large datasets, deriving immune signatures, ranking candidate targets, and supporting translation. This review summarizes recent work at that interface: immune heterogeneity and dysfunction across macrophage, NK, T, B, dendritic cell, and mast cell compartments; AI-assisted biomarker studies, repurposing, and network pharmacology, including natural products and traditional Chinese medicine; and practical limits that still affect clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.